Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer : Episode 2
Opinion
Video
ADCs in Breast Cancer: Mechanism of Action, and Components
Author(s):
Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.
EP: 1.Overview of Current ADCs in Breast Cancer
Now Viewing
EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components
EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia
EP: 5.Navigating SG-related Diarrhea
EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd
Video content above is prompted by the following:
- What are the different mechanisms between these antibody-drug conjugates (ADCs), as well as the different components that make up these ADCs (ie, drug, antibody, linker)?
- Please briefly comment on how the different ADC components relate to the mechanism of some of the ADC-related toxicities.
Related Videos
Related Content
